Seeking Alpha

Furiex Pharmaceuticals (FURX) announces its PPD-10558 drug for treating statin-associated...

Furiex Pharmaceuticals (FURX) announces its PPD-10558 drug for treating statin-associated myalgia "did not meet its primary efficacy endpoint" during Phase II trials. As a result, Furiex will discontinue further development work on PPD-10558. Shares are currently halted.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|